Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

University of Chicago, Chicago, Illinois, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Chicago, Illinois
Treatments:Biologic therapyHospital:University of Chicago
Drugs:Journal:Link
Date:Jan 2004

Description:

Patients: This Phase II trial involved 58 patients with hormone refractory prostate cancer. Median age was 72 years. All patients had received previous hormone therapy, 38 patients had received prior radiotherapy, and 42 patients had received prior surgery.

Treatment: The treatment consisted of Suramin (a drug typically used against trypanosomiasis – sleeping sickness).

Toxicity: Grade 3 or 4 toxicities included edema, elevated alkaline phosphatase, hematologic, bilirubin, pain, fatigue, anorexia, diarrhea, and respiratory.

Results: Median survival was 15.3 months.

Correspondence: Nicholas J. Vogelzang, MD




Back